Clinical Trial Update: Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial assessed P2Y12 receptor inhibition with prasugrel and ticagrelor in patients treated with thrombolysis for acute coronary syndrome; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome

Drugs mentioned

• BRILINTA (ticagrelor)
• EFFIENT (prasugrel hydrochloride)

Snippet

Sponsor: Federal University of São Paulo | Conditions: Acute Coronary Syndrome, Platelet Function | Phase 4 | Status: COMPLETED